Tomasson: Elranatamab is a bispecific antibody that binds to the BCMA on the tumor cells and the CD3-positive bone marrow ...
Antivirals such as nirmatrelvir/ritonavir (Paxlovid), remdesivir (Veklury), and molnupiravir (Lagevrio) remain approved or ...
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...
Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...
By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb ...
Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...
Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...
Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...
Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...
The firms partnered earlier this year to leverage each other's technologies and develop multiple T-cell receptor-guided T-cell engagers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback